Relay Therapeutics, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Sep 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for FGFR Inhibitors and Methods of Use Thereof (US 11,780,845) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for SHP2 Phosphatase Inhibitors and Methods of Making and Using the Same (US 11,890,281) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,529,347 | SHP2 Phosphatase Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,629,145 | SHP2 Phosphatase Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,591,336 | SUBSTITUTED PYRAZOLO[3,4-b]PYRAZINES AS SHP2 PHOSPHATASE INHIBITORS In force · High confidence | In force | High confidence | |
| US 10,934,302 | SHP2 Phosphatase Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,331,056 | SHP2 Phosphatase Inhibitors and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,084,447 | SHP2 Phosphatase Inhibitors and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,780,845 | FGFR Inhibitors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,890,281 | SHP2 Phosphatase Inhibitors and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 12,581,252 | SUBSTITUTED PYRROLO[3,4-b]PYRIDINES AS PI3K-ALPHA INHIBITORS In force · High confidence | In force | High confidence | |
| US 12,219,327 | Substituted Isoindolines as PI3K-ALPHA Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 12: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 4 abandoned · 1 no status recorded